‘Your Move, Human’: Analysts See Growth Potential in These 2 Robotics Stocks

In the 1950s, Isaac Asimov published his Robot novels, picturing a society in which autonomous robots were fully integrated into human society. His book probed the advantages and disadvantages of such integration, and predicted laws, devised in both computer programming and the courts, to govern the behavior of robots and their interactions with humans. His books were hopeful, imagining a universe in which robots were indispensable tools and partners for humans.

We’re not there yet, but we’re on the way. Simple industrial robots have been with us for decades, handling dangerous or repetitive factory tasks and increasing productivity on our assembly lines. More modern robots, and remotely controlled robotic manipulators, are revolutionizing miniaturized processes in high-tech manufacturing, and similar technologies are making inroads in the medical and surgical fields. And now AI is being added to the mix.

AI promises to bring fuller autonomy to the field of robotics. We’re already seeing early steps, in the form of self-driving vehicle technology. Robotaxis and robot delivery vehicles are starting to appear on our city streets, and several companies are working on AI-powered humanoid robots, as labor-saving devices built to fit seamlessly into our modern world.

Already, the global market in robotics is measured in billions of dollars. According to Fortune Business Insights, the global market for service robots was valued at $22.4 billion last year, and is expected to more than quadruple by 2032 and reach a value of ~$90.1 billion.

Expansion on that scale is sure to bring investment opportunities along with it, and the Street’s analysts are busy picking out which robotics stocks are likely winners. We used the TipRanks database to pinpoint two such stocks with sound growth potential; let’s give them a closer look.

Serve Robotics (SERV)

The first company we’ll look at here is Serve Robotis, a small-cap firm working on the next generation of autonomous delivery technologies. Serve spun off from Uber four years ago, and in that time the robotics company has completed tens of thousands of small deliveries, providing small autonomous delivery vehicles for larger partners such as Uber Eats and 7-Eleven. Serve is building its business around scalable multi-year contracts; the company is willing to start small and work its way up.

Prominent among Serve’s contracts is a multi-year deal with Uber Eats, under which Serve is in the process of deploying up to 2,000 delivery robots across numerous US markets. The agreement was inked in 2023, and is set to continue into next year. In an announcement made on August 18, Serve made public its acquisition of Vayu Robotis, an innovative company pioneering the use of large-scale AI models in urban robot navigation. The acquisition is expected to expand the roadmap used by Serve’s third-generation delivery robots and to expand Serve’s autonomy training capabilities. The transaction will be conducted almost entirely in stock and will include an up-front payment by Serve of 1,696,069 SERV shares to Vayu stockholders.

Serve’s business model is built around a small sidewalk delivery robot, a battery-powered wheeled vehicle approximately the size of a shopping cart. The company designed its delivery ‘bot around a simple question: Why deliver 2-pound burritos in 2-ton cars? Answering that question, the company designed a small robot with a cargo bin capable of holding four 16-inch pizzas, a travel speed of 11 miles per hour, and a range of 48 miles on a single charge.

Urban delivery, especially in the ‘last mile’ niche, is in high demand, and Serve is reaping the rewards. Earlier this year, the company delivered more than 120 new vehicles into its delivery fleet, and during Q2 the company increased its delivery volume by 78% over Q1. And, on August 5, the company announced a partnership with Little Caesar’s Pizza for deliveries in the Los Angeles area. Little Caesar’s is the third-largest pizza chain in the US.

Turning to the financials, Serve reported 2Q25 revenues of $642,000. This total was in line with expectations, and was up 36% year-over-year. The company runs a net loss, and in Q2 that loss came to 24 cents per share by non-GAAP measures, missing the forecast by 7 cents per share. Serve reported a strong liquidity position at the end of the quarter of $183 million. Also during the quarter, Serve launched activities in the Atlanta metro area and is planning to launch in Chicago in the near future.

Serve has caught the attention of Wedbush analyst Dan Ives, a well-known tech expert. Ives sees plenty of scope for Serve to grow and expand its business, writing of the company, “With plans to grow its autonomous robot fleet to 2,000 by the end of 2025, establish new partnerships, and launch operations in additional cities with favorable regulatory environments, Serve is strongly positioned to gain market share as demand rises for automation, operational efficiency, and sustainable delivery solutions. To navigate an increasingly competitive landscape, Serve is leveraging its first-mover advantage, deep industry partnerships, and proprietary autonomy stack to differentiate itself from both traditional delivery services and emerging robotics competitors with demand growing across the autonomous last-mile delivery space… We believe SERV will start to capitalize over the coming years as cities and businesses seek to modernize delivery infrastructure with Serve’s scalable, data-driven approach positioning it as a key enabler of the next wave of urban commerce.”

Ives goes on to rate SERV shares as an Outperform (i.e., Buy) and sets a $15 price target that suggests a one-year upside potential of 35%. (To watch Ives’ track record, click here)

This stock is flying somewhat under the radar, and its 3 recent analyst reviews split into 2 Buys and 1 Hold, giving the shares a Moderate Buy consensus rating. The stock is currently trading for $10.29, and its $19 average price target points toward an 85% gain in the next 12 months. (See SERV stock forecast)

PROCEPT BioRobotics (PRCT)

As we noted above, robotics are making inroads into the medical industry. Remotely controlled robotic devices allow surgeons to conduct microsurgical procedures, to reach inaccessible areas of the human body, and even to conduct operations from remote locations. The next stock on our list, PROCEPT BioRobotics, has set its focus on men’s health, specifically in the field of urological and prostate conditions. The company is a leader in treating BPH, or benign prostatic hyperplasia, a common and noncancerous enlargement of the prostate.

BPH treatment is a particularly sensitive area of men’s health, and many patients avoid treatment out of worries over the potential side effects. PROCEPT directly addresses this issue with its Aquablation therapy, a robotic-assisted, image-guided, heat-free waterjet treatment designed to correct BPH while avoiding negative effects on continence and sexual function. The numbers tell the story – according to PROCEPT, more than 99% of patients treated with Aquablation preserve continence after treatment, and 89% of patients avoided complications in sexual function. The company also reports that the positive effects of treatment are durable, with 94% of patients avoiding further BPH at 5 years post-treatment.

PROCEPT has just undergone big changes in its top-level leadership. On July 24, the company announced that CEO, Dr. Reza Zadno, will be retiring from his position as President, CEO, and Board member as of September 1. His post was taken by Larry Wood on September 2. Wood brings 40 years of experience as an executive in the medical science field.

This change in management took place in the wake of a solid second-quarter performance. PROCEPT’s 2Q25 report showed that the company’s quarterly revenue grew by almost 49% year-over-year, to reach $79.2 million and to beat the forecast by nearly $3 million. At the bottom line, the quarterly EPS loss came to 35 cents, yet 7 cents per share better than had been anticipated.

Covering this stock for Piper Sandler, analyst Matt O’Brien notes that PROCEPT has a solid market share in treating BPH, and also points out that the stock has an attractive valuation. Writing of PRCT, he says, “The company is on pace to have about 17.5% share of the domestic BPH market exiting this year. That compares quite favorably to the 10.5% share they held last year and ~6.5% they were in ’23. We believe investors are missing this acceleration in share taking within the overall category and it demonstrates the utility of the technology they are selling, which we continue to anticipate will be standard of care eventually… The stock is now trading near all-time lows on an EV/Sales basis, despite continued business momentum. We view current levels as attractive and would recommend investors build positions here.”

O’Brien gives this stock an Overweight (i.e., Buy) rating, which he supports with a $55 price target that implies room for a 39% upside on the one-year horizon. (To watch O’Brien’s track record, click here)

This medical tech stock has 11 recent analyst reviews on file, including 10 Buys and 1 Hold, for a Strong Buy consensus rating. The stock is currently priced at $39.57, and its $69 average price target is even more bullish than the Piper Sandler view, suggesting a robust upside for the next 12 months of 74%. (See PRCT stock forecast)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.